Publication biases and phase II trials investigating anticancer targeted therapies

Author： Penel Nicolas   Adenis Antoine  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.27, Iss.3, 2009-06, pp. : 287-288

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lower toxicity with targeted anticancer agents in phase I trials

By  

Reactions Weekly, Vol. 1, Iss. 1416, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Therapies currently in Phase II trials for malignant pleural mesothelioma

By Pinton Giulia   Manente Arcangela Gabriella   Tavian Daniela   Moro Laura   Mutti Luciano  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 10, 2013-10 ,pp. : 1255-1263

Informa Healthcare

Access to resources Recommend Favorite

Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials

By Ederhy Stephane  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 611-615

Springer Publishing Company

Access to resources Recommend Favorite

Targeted Anti-Cancer Therapies for Renal Cancer

By Amato Robert J.   Jac Jaroslaw  

Drugs, Vol. 66, Iss. 17, 2006-01 ,pp. : 2161-2171

Adis International

Access to resources Recommend Favorite

Discovery of BRM Targeted Therapies: Novel Reactivation of an Anticancer Gene

By  

Letters in Drug Design & Discovery, Vol. 8, Iss. 1, 2011-01 ,pp. : 93-99

Bentham Science Publishers

Access to resources Recommend Favorite